



- (51) **International Patent Classification:**
A61P 1/04 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/US2024/021530
- (22) **International Filing Date:**
26 March 2024 (26.03.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/492,425 27 March 2023 (27.03.2023) US
- (71) **Applicant:** **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).
- (72) **Inventors:** **ASRAT, Seblewongel**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **KAMAT, Siddhesh A.**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **LIU, Xia**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road,

Tarrytown, New York 10591 (US). **MALONEY, Jennifer**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MCCANN, Eilish C.**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ORENGO, Jamie M.**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SCOTT, George C.**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **SHABBIR, Arsalan Q.**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

- (74) **Agent:** **EVANS, Daniel R.** et al.; Merchant & Gould P.C., P.O. BOX 2903, MINNEAPOLIS, Minnesota 55402-0903 (US).

- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

- (54) **Title:** METHODS FOR TREATING EOSINOPHILIC GASTROENTERITIS BY ADMINISTERING AN IL-4R ANTAGONIST




FIG. 1

- (57) **Abstract:** Methods for treating eosinophilic gastritis or eosinophilic gastroenteritis are provided. In one aspect, the methods comprise administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))